Viking's leading drug candidate could be a blockbuster in the weight loss market, which experts believe could grow to $150 ...

Kyle Richards and Mauricio Umansky's daughter, Sophia Umansky, posted a TikTok and revealed that she’s been taking Mounjaro for around four months. She explained that she believes the weight-loss drug ...

But Eli Lilly CEO David Ricks waved off the deal Thursday, telling Yahoo Finance in an interview that the company is focused ...

CVS Health's pharmacy benefits manager said weight-loss drugs from rival drugmaker Novo Nordisk will become the preferred ...

CVS Health Corp.’s drug-benefits unit negotiated a deal to make Novo Nordisk A/S’s Wegovy more widely available to its ...

Shares of Eli Lilly (NYSE: LLY) are sliding on Thursday. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) gained 1% and the Nasdaq Composite (NASDAQINDEX: ^IXIC) gained 1.9%. The pharmaceutical ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

Eli Lilly on Thursday downplayed CVS Health's decision to drop the company's obesity drug Zepbound from some lists of ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click ...

CVS said it will expand access to blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark.

Eli Lilly CEO Dave Ricks took a stand against Trump's tariffs in a Q1 earnings call. The medicine company has strong operations for obesity and weight loss drugs in Ireland.